HC Wainwright & Co. maintains Greenwich LifeSciences at Buy, raises price target to $70 from $69

HC Wainwright & Co. kept its Buy rating on Greenwich LifeSciences and increased its price target to $70 from $69, suggesting a 274.3% upside from the Nov 17 close of $18.70.

Original reporting
Published Nov 18, 2026, 12:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 12:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. maintains Greenwich LifeSciences at Buy, raises price target to $70 from $69 — source image
Decision brief

The 30-second read

Low
01

Why it matters

For traders, the actionable element is the incremental sentiment from the higher target, but the lack of new company-specific operational or clinical information limits conviction.

02

Market read

A modest analyst price-target raise for the subject company, likely to have limited impact absent new fundamentals.

03

What to watch

Without details on what changed in the valuation assumptions, traders may treat the move as low-conviction and wait for primary catalysts (trial/regulatory/earnings).

Relevance 4/10Novelty 4/10Timing: today, as the analyst price-target update is published

Background

The piece is an analyst note update: HC Wainwright maintains a Buy rating and raises the price target by $1.

Market effects

Minimal sector read-through because the update is single-name analyst valuation rather than a sector-wide catalyst.

No clear regional spillover indicated.

No global macro or cross-market linkage described.

Counterpoint

The target increase may reflect model recalibration rather than new company fundamentals, so the market may discount it quickly.

Key entities

  • Greenwich LifeSciences

    Subject of the analyst rating and price-target update.

  • HC Wainwright & Co.

    Brokerage issuing the Buy rating and raised price target.

Related articles

$GLSIMedAI 8/10

RedChip Companies, Inc.: Greenwich LifeSciences Interview to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

Greenwich LifeSciences (GLSI) will be featured on the RedChip Small Stocks, Big Money show on Bloomberg TV and CNBC. CEO Snehal Patel discusses GLSI-100, an immunotherapy for HER2-positive breast cancer, highlighting an 80% reduction in recurrence in trials. The company is expanding its Phase III trial and exploring broader patient eligibility. GLSI aims to double its target population to 88,000 patients in the U.S. and Europe.

$GLSIMedAI 8/10

Greenwich LifeSciences presents at BIO-Europe 2026 in Cologne

Greenwich LifeSciences (GLSI) presented at BIO-Europe 2026, discussing its phase three trial (Flamingo-1) for early breast cancer. The trial, led by Baylor College of Medicine, has 180 sites in the US and Europe, with plans to expand. The company reported an 80% reduction in recurrence rate in phase two trials. GLSI is publicly traded, has raised $60M since IPO, and is fast track designated. Management owns 75-85% of the company, with a low float and extended lockup until January 2027.

$GLSIMedAI 8/10

Greenwich Advances FLAMINGO-01 Phase III Trial With Strategic Enrollment Changes

Greenwich LifeSciences (GLSI) said U.S. and European regulators approved changes to its FLAMINGO-01 Phase III trial of GLSI-100 for breast cancer recurrence. The DSMB recommended continuing without changes. Enrollment now includes non-HLA-A*02 patients, expected to more than double enrollment rate. In a 250-patient arm, preliminary results show a 70-80% recurrence reduction. Cash was about $8.9M at June 30, 2026.